Lv1
38 积分 2024-01-15 加入
Deep exploration of sotorasib-related hepatobiliary AEs: Based on FDA Adverse Event reporting system
1小时前
待确认
Glecirasib with or without cetuximab in previously treated locally advanced or metastatic colorectal cancer with KRASG12C mutation (JAB-21822-1002 and JAB-21822-1007): two open-label, non-randomised phase 1/2 trials
2个月前
已完结
实体肿瘤患者伴发肺炎临床诊疗实践中国专家共识（2024版）
6个月前
已完结
Changing epidemiology and etiology of upper and lower gastrointestinal bleeding
7个月前
已完结
D3S-001 in advanced solid tumors with KRASG12C mutations: a phase 1 trial
8个月前
已完结
A Convergent Approach to Resorcinolic Macrolides to Expand Structural Diversity
8个月前
已完结
Use of new approach methodology for hepatic safety assessment of covalent inhibitor drug candidates
8个月前
已完结
Two first-generation KRAS inhibitor safety profiles: a disproportionality analysis of individual reports from the FDA adverse event reporting system
8个月前
已完结
皖公网安备34019202002308
